Results 1 - 10 of 11 : 1 2 Next
Get over your fear of failure.
Higher revenue and lower expenses make for a good quarter.
More Extrinsic Growth From Inverness on the Way
Trading stock for revenues is becoming second nature for Inverness.
Now might be a great time to load up on cutting-edge drug makers.
This Just In: Mergers Do Indeed Lower Costs
Thermo Fisher merger continues to progress nicely.
The company sees double-digit growth in both sales and earnings in Q1.
More Drugmaker Growth Without the FDA
All that high-tech equipment has to come from somewhere.
Extrinsic Growth From Inverness
Acquiring six companies in a year and a half, oh my!
Biosite has two companies vying to acquire it.
The company wields pricing power, which is helping margins.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK